Skip to main content
Top
Published in: Internal and Emergency Medicine 6/2018

01-09-2018 | IM - ORIGINAL

Incidence, features, in-hospital outcomes and predictors of in-hospital mortality associated with toxic megacolon hospitalizations in the United States

Authors: Rajkumar Doshi, Jiten Desai, Yash Shah, Dean Decter, Shreyans Doshi

Published in: Internal and Emergency Medicine | Issue 6/2018

Login to get access

Abstract

Toxic megacolon (TM) is a potentially fatal condition characterized by non-obstructive colonic dilatation and systemic toxicity. It is most commonly caused by inflammatory bowel disease (IBD). Limited data for TM are available demonstrating incidence, in-hospital outcomes and predictors of mortality. We sought to investigate incidence, characteristics, mortality and predictors of mortality associated with it. Data were obtained from the Healthcare Cost and Utilization Project (HCUP)’s Nationwide Inpatient Sample (NIS) database from January 2010 through December 2014. An analysis was performed on SAS 9.4 (SAS Institute Inc., Cary, NC). Patients below 18 years were excluded. A mixed-effects logistic regression model was developed to analyze predictors of mortality. Thus, 8139 (weighted) cases of TM were diagnosed between 2010 and 2014. TM is more prevalent in women (56.4%) than in men (43.6%), with a mean age of onset at 62.4 years, affecting whites (79.7%) more than non-whites. The most common reason for hospital admission included IBD (51.6%) followed by septicemia (10.2%) and intestinal infections (4.1%). Mean length of stay was 9.5 days and overall in-hospital mortality was 7.9%. Other complications included surgical resection of the large intestine (11.5%) and bowel obstruction (10.9%). Higher age, neurological disorder, coagulopathy, chronic pulmonary disease, heart failure, and renal failure were associated with greater risk of in-hospital mortality. TM is a serious condition with high in-hospital mortality. Management of TM requires an inter-disciplinary team approach with close monitoring. Patients with positive predictors in our study require special attention to prevent excessive in-hospital mortality.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bartram CI (1977) Radiology in the current assessment of ulcerative colitis. Gastrointest Radiol 1(4):383–392PubMed Bartram CI (1977) Radiology in the current assessment of ulcerative colitis. Gastrointest Radiol 1(4):383–392PubMed
3.
go back to reference Tomita R, Tanjoh K, Fujisaki S, Fukuzawa M (2000) Peptidergic nerves in the colon of patients with ulcerative colitis. Hepatogastroenterology 47(32):400–404PubMed Tomita R, Tanjoh K, Fujisaki S, Fukuzawa M (2000) Peptidergic nerves in the colon of patients with ulcerative colitis. Hepatogastroenterology 47(32):400–404PubMed
4.
go back to reference Tomita R, Tanjoh K (1998) Role of nitric oxide in the colon of patients with ulcerative colitis. World J Surg 22(1):88–91 [discussion 92] CrossRefPubMed Tomita R, Tanjoh K (1998) Role of nitric oxide in the colon of patients with ulcerative colitis. World J Surg 22(1):88–91 [discussion 92] CrossRefPubMed
5.
go back to reference Pons L, Droy-Lefaix MT, Bueno L (1992) Leukotriene D4 participates in colonic transit disturbances induced by intracolonic administration of trinitrobenzene sulfonic acid in rats. Gastroenterology 102(1):149–156CrossRefPubMed Pons L, Droy-Lefaix MT, Bueno L (1992) Leukotriene D4 participates in colonic transit disturbances induced by intracolonic administration of trinitrobenzene sulfonic acid in rats. Gastroenterology 102(1):149–156CrossRefPubMed
6.
go back to reference Snape WJ Jr, Kao HW (1988) Role of inflammatory mediators in colonic smooth muscle function in ulcerative colitis. Dig Dis Sci 33(3 Suppl):65S–70SCrossRefPubMed Snape WJ Jr, Kao HW (1988) Role of inflammatory mediators in colonic smooth muscle function in ulcerative colitis. Dig Dis Sci 33(3 Suppl):65S–70SCrossRefPubMed
10.
go back to reference Greenstein AJ, Sachar DB, Gibas A, Schrag D, Heimann T, Janowitz HD, Aufses AH Jr (1985) Outcome of toxic dilatation in ulcerative and Crohn’s colitis. J Clin Gastroenterol 7(2):137–143CrossRefPubMed Greenstein AJ, Sachar DB, Gibas A, Schrag D, Heimann T, Janowitz HD, Aufses AH Jr (1985) Outcome of toxic dilatation in ulcerative and Crohn’s colitis. J Clin Gastroenterol 7(2):137–143CrossRefPubMed
12.
go back to reference Roys G, Kaplan MS, Juler GL (1977) Surgical management of toxic megacolon. Am J Gastroenterol 68(2):161–166PubMed Roys G, Kaplan MS, Juler GL (1977) Surgical management of toxic megacolon. Am J Gastroenterol 68(2):161–166PubMed
13.
go back to reference Hartong WA, Arvanitakis C, Skibba RM, Klotz AP (1977) Treatment of toxic megacolon. A comparative review of 29 patients. Am J Dig Dis 22(3):195–200CrossRefPubMed Hartong WA, Arvanitakis C, Skibba RM, Klotz AP (1977) Treatment of toxic megacolon. A comparative review of 29 patients. Am J Dig Dis 22(3):195–200CrossRefPubMed
15.
go back to reference Strauss RJ, Flint GW, Platt N, Levin L, Wise L (1976) The surgical management of toxic dilatation of the colon: a report of 28 cases and review of the literature. Ann Surg 184(6):682–688CrossRefPubMedPubMedCentral Strauss RJ, Flint GW, Platt N, Levin L, Wise L (1976) The surgical management of toxic dilatation of the colon: a report of 28 cases and review of the literature. Ann Surg 184(6):682–688CrossRefPubMedPubMedCentral
16.
go back to reference Danovitch SH (1989) Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am 18(1):73–82PubMed Danovitch SH (1989) Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am 18(1):73–82PubMed
19.
go back to reference Grundfest-Broniatowski S, Quader M, Alexander F, Walsh RM, Lavery I, Milsom J (1996) Clostridium difficile colitis in the critically ill. Dis Colon Rectum 39(6):619–623CrossRefPubMed Grundfest-Broniatowski S, Quader M, Alexander F, Walsh RM, Lavery I, Milsom J (1996) Clostridium difficile colitis in the critically ill. Dis Colon Rectum 39(6):619–623CrossRefPubMed
23.
go back to reference Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8–27CrossRefPubMed Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8–27CrossRefPubMed
26.
go back to reference Jalan KN, Sircus W, Card WI, Falconer CW, Bruce CB, Crean GP, McManus JP, Small WP, Smith AN (1969) An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology 57(1):68–82PubMed Jalan KN, Sircus W, Card WI, Falconer CW, Bruce CB, Crean GP, McManus JP, Small WP, Smith AN (1969) An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology 57(1):68–82PubMed
28.
go back to reference Trudel JL, Deschenes M, Mayrand S, Barkun AN (1995) Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum 38(10):1033–1038CrossRefPubMed Trudel JL, Deschenes M, Mayrand S, Barkun AN (1995) Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum 38(10):1033–1038CrossRefPubMed
33.
go back to reference Imbriaco M, Balthazar EJ (2001) Toxic megacolon: role of CT in evaluation and detection of complications. Clin Imaging 25(5):349–354CrossRefPubMed Imbriaco M, Balthazar EJ (2001) Toxic megacolon: role of CT in evaluation and detection of complications. Clin Imaging 25(5):349–354CrossRefPubMed
37.
go back to reference Tapani MJ, Olavi KH (2014) Surgical management of toxic megacolon. Hepatogastroenterology 61(131):638–641PubMed Tapani MJ, Olavi KH (2014) Surgical management of toxic megacolon. Hepatogastroenterology 61(131):638–641PubMed
Metadata
Title
Incidence, features, in-hospital outcomes and predictors of in-hospital mortality associated with toxic megacolon hospitalizations in the United States
Authors
Rajkumar Doshi
Jiten Desai
Yash Shah
Dean Decter
Shreyans Doshi
Publication date
01-09-2018
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 6/2018
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-018-1889-8

Other articles of this Issue 6/2018

Internal and Emergency Medicine 6/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.